CorMedix (CRMD) Receives Request for Additional Data for Neutrolin in the EU

Article Comments (0)

CorMedix Inc.(NYSE Amex: CRMD) announces the receipt of a request for additional information and data, including six month stability data on the third and final test batch from TUV-SUD (the Testing and Certification Group) and MEB-Netherlands (the Competent Authority) on the CE Mark application for Neutrolin® in the EU. Upon delivery of the requested information, the Company believes that Neutrolin® will enter a third and final round of review to finalize the CE Mark. CorMedix anticipates providing such additional information and data in late 3Q or early 4Q 2012. As a result, CorMedix now anticipates a final review and determination regarding its CE Mark application by the end of 4Q 2012.

CorMedix is currently in the final stages of completing its commercialization plan and is in discussions with several potential partners regarding the launch of Neutrolin® in Europe. Based on the status of such discussions CorMedix continues to target a commercial launch for 4Q 2012 / 1Q 2013.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Cytokinetics (CYTK) ATOMIC-AHF Results to Be Presented at ESC Congress 2013 (AMGN)
• Genetic Tech (GENE) Updates on Impact of SCOTUS Ruling on Gene Patenting
• NVIDIA (NVDA) Changes Business Model; Plans to License GPU Technology

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?